Vectura Group PLC (VEC) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Vectura Group PLC (LON:VEC) have received an average recommendation of “Buy” from the ten research firms that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is GBX 174.86 ($2.42).

Several analysts recently weighed in on VEC shares. Peel Hunt restated a “hold” rating and issued a GBX 160 ($2.21) price target on shares of Vectura Group in a research note on Tuesday, October 31st. Shore Capital restated a “buy” rating on shares of Vectura Group in a research note on Thursday, November 9th. Numis Securities cut their price target on Vectura Group from GBX 205 ($2.83) to GBX 170 ($2.35) and set a “buy” rating on the stock in a research note on Thursday, November 9th. Panmure Gordon restated a “buy” rating and issued a GBX 150 ($2.07) price target on shares of Vectura Group in a research note on Thursday, November 9th. Finally, JPMorgan Chase & Co. cut their price target on Vectura Group from GBX 180 ($2.49) to GBX 175 ($2.42) and set an “overweight” rating on the stock in a research note on Friday, November 10th.

Vectura Group (LON VEC) traded down GBX 3.25 ($0.04) during trading on Tuesday, hitting GBX 78.10 ($1.08). The company had a trading volume of 2,691,291 shares, compared to its average volume of 4,980,000. Vectura Group has a 52 week low of GBX 77.30 ($1.07) and a 52 week high of GBX 166.97 ($2.31).

COPYRIGHT VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/13/vectura-group-plc-vec-receives-consensus-recommendation-of-buy-from-analysts.html.

About Vectura Group

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply